Lipid-lowering effects of oleanolic acid in hyperlipidemic patients.

[1]  Lanlan Wang,et al.  The effects of oleanolic acid on atherosclerosis in different animal models , 2017, Acta biochimica et biophysica Sinica.

[2]  Siyu Chen,et al.  Hypolipidemic effect of oleanolic acid is mediated by the miR‐98‐5p/PGC‐1β axis in high‐fat diet‐induced hyperlipidemic mice , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  S. Jamshidi,et al.  Association of serum lipid indices and statin consumption with periodontal status. , 2016, Oral diseases.

[4]  C. Ekhart,et al.  Muscle rupture associated with statin use. , 2016, British journal of clinical pharmacology.

[5]  R. Rodríguez-Rodríguez.  Oleanolic acid and related triterpenoids from olives on vascular function: molecular mechanisms and therapeutic perspectives. , 2015, Current medicinal chemistry.

[6]  Xu-Feng Huang,et al.  The molecular mechanisms underpinning the therapeutic properties of oleanolic acid, its isomer and derivatives for type 2 diabetes and associated complications. , 2014, Molecular nutrition & food research.

[7]  M. del Ben,et al.  Modern approach to the clinical management of non-alcoholic fatty liver disease. , 2014, World journal of gastroenterology.

[8]  Wei Zhang,et al.  Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects , 2013, Molecular and Cellular Endocrinology.

[9]  M. Banach,et al.  The role of fibrate treatment in dyslipidemia: an overview. , 2013, Current pharmaceutical design.

[10]  T. Iseli,et al.  Oleanolic Acid Reduces Hyperglycemia beyond Treatment Period with Akt/FoxO1-Induced Suppression of Hepatic Gluconeogenesis in Type-2 Diabetic Mice , 2012, PloS one.

[11]  T. A. Jacobson,et al.  Statin-induced myopathy: a review and update , 2011, Expert opinion on drug safety.

[12]  Rui Liu,et al.  Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP kinases. , 2010, Chemico-biological interactions.

[13]  Y. Li,et al.  Antidiabetic and antioxidant effects of oleanolic acid from Ligustrum lucidum Ait in alloxan‐induced diabetic rats , 2009, Phytotherapy research : PTR.

[14]  M. Vranic,et al.  Oleanolic acid enhances insulin secretion in pancreatic β‐cells , 2008, FEBS letters.

[15]  E. Liberopoulos,et al.  Fibrate-associated adverse effects beyond muscle and liver toxicity. , 2008, Current pharmaceutical design.

[16]  E. Liberopoulos,et al.  Statin-associated adverse effects beyond muscle and liver toxicity. , 2007, Atherosclerosis.

[17]  D. Sautereau,et al.  Hépatite aiguë cytolytique et cholestatique induite par le fénofibrate , 2003 .

[18]  H. Milionis,et al.  Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid , 2010 .

[19]  B. Golomb,et al.  Statin Adverse Effects , 2008, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[20]  F. Shode,et al.  Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. , 2003, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[21]  D. Sautereau,et al.  [Acute cytolytic and cholestatic hepatitis induced by fenofibrate]. , 2003, Gastroenterologie clinique et biologique.

[22]  Jie Liu.  Pharmacology of oleanolic acid and ursolic acid , 2003 .

[23]  D. Horrobin.  The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. , 1988, Prostaglandins, leukotrienes, and essential fatty acids.